The quarter beat the published bar. Revenue reached $388.2 million versus a published consensus of roughly $368.7 million, while adjusted diluted EPS was $1.55 versus about $1.31 expected.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Worldwide revenue | $388.2M | $378.0M; consensus ~$368.7M |
| GAAP diluted EPS | $1.11 | $1.12 |
| Adjusted diluted EPS | $1.55 | $1.57; consensus ~$1.31 |
| Adjusted operating income | $142.0M | $152.6M |
| Free cash flow | $89.9M | $79.1M |
The underlying mix is less clean than the headline beat. Revenue grew only 2.7% year over year, with PYLARIFY down 4.1% to $240.4 million; DEFINITY rose 5.2% to $88.3 million, while Neuraceq contributed $39.6 million and strategic partnerships added $19.9 million. The shift away from the legacy SPECT business and the new Neuraceq contribution helped offset continued PYLARIFY pressure (Consolidated Revenues Analysis).
Profit quality weakened despite the earnings beat. Adjusted operating income fell 6.9% to $142.0 million, and adjusted net income declined 5.1% to $104.9 million; the adjusted operating margin compressed to 36.6% from 40.4% a year earlier (GAAP to Non-GAAP Reconciliation). Stronger-than-expected EPS therefore reflects a combination of expectation reset, lower share count, and adjustment items—not accelerating operating momentum.
The merger now matters more than the standalone outlook. The Curium transaction was announced on August 3, 2026, before this earnings release, so its headline terms—$102.50 per share in cash plus CVRs worth up to $12.00—are confirmation rather than new information in this filing. Lantheus suspended full-year 2026 guidance and canceled the earnings call because of the pending deal, removing the forward operating benchmark investors would normally use (Exhibit 99.1, merger and guidance update).
Net read: a financial beat, but a strategically interrupted one. Cash generation improved to $92.2 million from operations and $89.9 million of free cash flow, while cash rose to $593.3 million at June 30 (Cash Flow Reconciliation; Condensed Consolidated Balance Sheets). That supports the balance sheet, but the core PYLARIFY decline, falling adjusted margins, and withdrawn guidance keep the overall signal mixed rather than clearly positive.
Read the original 8-K on SEC EDGAR ↗